Thrombin-Activatable Fibrinolysis Inhibitor

Publisher： Bentham Science Publishers

E-ISSN： 1875-533x|11|17|2335-2348

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.11, Iss.17, 2004-09, pp. : 2335-2348

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Recent Developments in Thrombin-Activatable Fibrinolysis Inhibitor Research

By  

Mini Reviews in Medicinal Chemistry, Vol. 9, Iss. 10, 2009-09 ,pp. : 1165-1173

Bentham Science Publishers

Access to resources Recommend Favorite

Ximelagatran: the first oral direct thrombin inhibitor

By Crowther Mark A   Weitz Jeffrey I  

Expert Opinion on Investigational Drugs, Vol. 13, Iss. 4, 2004-04 ,pp. : 403-413

Informa Healthcare

Access to resources Recommend Favorite

Ximelagatran: An Oral Direct Thrombin Inhibitor for Anticoagulant Therapy

By  

Letters in Drug Design & Discovery, Vol. 2, Iss. 7, 2005-11 ,pp. : 503-506

Bentham Science Publishers

Access to resources Recommend Favorite

Clinical Pharmacokinetics and Pharmacodynamics of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate

By Stangier Joachim  

Clinical Pharmacokinetics, Vol. 47, Iss. 5, 2008-01 ,pp. : 285-295

Adis International

Access to resources Recommend Favorite

Argatroban, a direct thrombin inhibitor for heparin-induced thrombocytopaenia: present and future perspectives

By Serebruany Michael V   Malinin Alex I   Serebruany Victor L  

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 1, 2006-01 ,pp. : 81-89

Informa Healthcare

Access to resources Recommend Favorite